Literature DB >> 2668787

Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up.

G P Sechi1, M Zuddas, M Piredda, V Agnetti, G Sau, M L Piras, S Tanca, G Rosati.   

Abstract

We studied the effects of carbamazepine (CBZ) (400 and 600 mg per day) in 10 patients with cerebellar tremors in a single-blind manner. All patients improved on a clinical rating scale and by accelerometric recording; there was no improvement with placebo. Our data suggest that CBZ may be a valuable drug in cerebellar tremors.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2668787     DOI： 10.1212/wnl.39.8.1113

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  13 in total

1.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Neurology.

Authors:  A N Gale; J M Gibbs; A H Schapira; P K Thomas
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

3.  Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.

Authors:  Pasquale Striano; Antonietta Coppola; Giovanni Vacca; Federico Zara; Vincenzo Brescia Morra; Giuseppe Orefice; Salvatore Striano
Journal:  J Neurol       Date:  2006-05-12       Impact factor: 4.849

4.  Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor.

Authors:  G P Rice; J Lesaux; P Vandervoort; L Macewan; G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Head tremor secondary to MS resolved with rituximab.

Authors:  Chakorn Chansakul; Guillermo Moguel-Cobos; Roberto Bomprezzi
Journal:  Neurol Sci       Date:  2011-05-10       Impact factor: 3.307

6.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

7.  Evaluation of three different ways of assessing tremor in multiple sclerosis.

Authors:  S H Alusi; J Worthington; S Glickman; L J Findley; P G Bain
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

8.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

9.  Investigation of the risk of valproic acid-induced tremor: clinical, neuroimaging, and genetic factors.

Authors:  Lili Lan; Xu Zhao; Si Jian; Cun Li; Man Wang; Qing Zhou; Shanshan Huang; Suiqiang Zhu; Huicong Kang; Heidi E Kirsch
Journal:  Psychopharmacology (Berl)       Date:  2021-10-30       Impact factor: 4.530

Review 10.  The treatment of tremor.

Authors:  Susanne A Schneider; Günther Deuschl
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.